Cabaser 1 mg Tablets Summary of Product Characteristics SmPC emc

It is very unusual for cabergoline to cause clinically significant heart problems, but you should alert your doctor if you developed shortness of breath or ankle swelling. Other drugs may affect cabergoline, including prescription and over-the-counter medicines, vitamins, and herbal products. You should not use cabergoline if you have uncontrolled high blood pressure, a heart valve disorder, or a condition called fibrosis (growth of excess tissue in or around internal organs). You should not use cabergoline if you are allergic to any type of ergot medicine.

• Dopamine antagonists such as antipsychotics and metoclopramide counteract some effects of cabergoline.
• Human bioavailability has not been determined since the drug is intended for oral use only.
• Cabergoline should be discontinued if an echocardiogram reveals new or worsened valvular regurgitation, valvular restriction, valve leaflet thickening or fibrotic valvular disease (see section 4.3).
• Other reported clinical experience has not identified differences in responses between the elderly and younger patients.
• After oral administration of the labelled compound, radioactivity was rapidly absorbed from the gastrointestinal tract as the peak of radioactivity in plasma was between 0.5 and 4 hours.

Similarly, check with your doctor or pharmacist before taking any new medicines while taking this one, to ensure that the combination is safe. Before taking cabergoline, tell your doctor or pharmacist if you are allergic to it; or to other ergot medications (such as ergotamine); or if you have any other allergies. This product may contain inactive ingredients, which can cause allergic reactions or other problems. No information is available about the interaction between cabergoline and other ergot alkaloids; therefore, the concomitant use of these medications during long-term treatment with cabergoline is not recommended.

Patients with Renal Impairment

Due to the long half-life of the drug and limited data on in utero exposure, women planning to become pregnant should discontinue cabergoline one month before intended conception. If conception occurs during therapy, treatment should be discontinued as soon as pregnancy is confirmed to limit foetal exposure to the drug. Symptomatic hypotension can occur with cabergoline administration for any indication. Cabergoline is contraindicated in patients with hepatic insufficiency and with toxaemia of pregnancy.

Are you currently using Cabergoline?

This information is intended for patients receiving care in Brighton & Hove or Haywards Heath. Cabergoline is a long-acting medicine, which only needs to be taken once or twice a week. The easiest way to lookup drug information, identify pills, check interactions and set up your own personal medication records.

Cabergoline side effects

Should pregnancy occur during treatment, https://zalewajka.com/maximizing-muscle-growth-proven-strategies-for/ is to be discontinued. Depending on your prolactinoma, your symptoms and your situation, you may need no treatment at all, or there may be alternatives such as oestrogen or testosterone treatment. If you are not able to tolerate treatment with cabergoline, or if it is not effective in your case, there are similar medications that can be considered, or other treatment options including pituitary surgery. There were maternotoxic effects but no teratogenic effects in mice given Cabergoline at doses up to 8 mg/kg/day (approximately 55 times the maximum recommended human dose) during the period of organogenesis. After oral dosing of radioactive Cabergoline to five healthy volunteers, approximately 22% and 60% of the dose was excreted within 20 days in the urine and feces, respectively. Less than 4% of the dose was excreted unchanged in the urine.